198 related articles for article (PubMed ID: 28774410)
1. What is new on HBsAg and other diagnostic markers in HBV infection?
Höner Zu Siederdissen C; Maasoumy B; Cornberg M
Best Pract Res Clin Gastroenterol; 2017 Jun; 31(3):281-289. PubMed ID: 28774410
[TBL] [Abstract][Full Text] [Related]
2. New viral biomarkers for Hepatitis B: Are we able to change practice?
Höner Zu Siederdissen C; Maasoumy B; Cornberg M
J Viral Hepat; 2018 Nov; 25(11):1226-1235. PubMed ID: 30187603
[TBL] [Abstract][Full Text] [Related]
3. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency.
Wong DK; Seto WK; Fung J; Ip P; Huang FY; Lai CL; Yuen MF
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1004-10.e1. PubMed ID: 23376799
[TBL] [Abstract][Full Text] [Related]
4. Nobiletin, a novel inhibitor, inhibits HBsAg production and hepatitis B virus replication.
Hu Z; Hu J; Ren F; Xu H; Tan M; Wang Q; Ren J
Biochem Biophys Res Commun; 2020 Mar; 523(3):802-808. PubMed ID: 31954513
[TBL] [Abstract][Full Text] [Related]
5. Latest developments in the treatment of hepatitis B.
Dandri M; Petersen J
Minerva Gastroenterol Dietol; 2016 Mar; 62(1):88-102. PubMed ID: 26448309
[TBL] [Abstract][Full Text] [Related]
6. HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide analogues.
Wang B; Carey I; Bruce M; Montague S; Dusheiko G; Agarwal K
J Viral Hepat; 2018 Aug; 25(8):886-893. PubMed ID: 29532589
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA.
Wong DK; Seto WK; Cheung KS; Chong CK; Huang FY; Fung J; Lai CL; Yuen MF
Liver Int; 2017 Jul; 37(7):995-1001. PubMed ID: 27992681
[TBL] [Abstract][Full Text] [Related]
8. How to interpret viral markers in the management of chronic hepatitis B infection.
Riveiro-Barciela M; Pericàs JM; Buti M
Clin Microbiol Infect; 2022 Mar; 28(3):355-361. PubMed ID: 34768018
[TBL] [Abstract][Full Text] [Related]
9. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
[TBL] [Abstract][Full Text] [Related]
10. Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy.
Cheung KS; Seto WK; Wong DK; Lai CL; Yuen MF
J Viral Hepat; 2017 Aug; 24(8):654-661. PubMed ID: 28185363
[TBL] [Abstract][Full Text] [Related]
11. Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients?
Sheldon J; Ramos B; Toro C; Ríos P; Martínez-Alarcón J; Bottecchia M; Romero M; Garcia-Samaniego J; Soriano V
Antivir Ther; 2008; 13(1):97-102. PubMed ID: 18389903
[TBL] [Abstract][Full Text] [Related]
12. Role of Biomarkers in Guiding Cure of Viral Hepatitis B.
Buti M; Riveiro-Barciela M; Rodríguez-Frías F; Tabernero D; Esteban R
Semin Liver Dis; 2020 Feb; 40(1):49-60. PubMed ID: 31805583
[TBL] [Abstract][Full Text] [Related]
13. Inhibiting the Secretion of Hepatitis B Surface Antigen (HBsAg) to Treat Hepatitis B Infection- a Review.
Baugh SDP
Infect Disord Drug Targets; 2017; 17(1):24-35. PubMed ID: 28056752
[TBL] [Abstract][Full Text] [Related]
14. Serum Hepatitis B Virus DNA, RNA, and HBsAg: Which Correlated Better with Intrahepatic Covalently Closed Circular DNA before and after Nucleos(t)ide Analogue Treatment?
Gao Y; Li Y; Meng Q; Zhang Z; Zhao P; Shang Q; Li Y; Su M; Li T; Liu X; Zhuang H
J Clin Microbiol; 2017 Oct; 55(10):2972-2982. PubMed ID: 28747369
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D.
Maasoumy B; Wiegand SB; Jaroszewicz J; Bremer B; Lehmann P; Deterding K; Taranta A; Manns MP; Wedemeyer H; Glebe D; Cornberg M
Clin Microbiol Infect; 2015 Jun; 21(6):606.e1-10. PubMed ID: 25700889
[TBL] [Abstract][Full Text] [Related]
16. Distinct patterns of serum hepatitis B core-related antigen during the natural history of chronic hepatitis B.
Zhang ZQ; Zhang XN; Lu W; Wang YB; Weng QC; Feng YL
BMC Gastroenterol; 2017 Dec; 17(1):140. PubMed ID: 29202690
[TBL] [Abstract][Full Text] [Related]
17. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.
Boni C; Laccabue D; Lampertico P; Giuberti T; Viganò M; Schivazappa S; Alfieri A; Pesci M; Gaeta GB; Brancaccio G; Colombo M; Missale G; Ferrari C
Gastroenterology; 2012 Oct; 143(4):963-73.e9. PubMed ID: 22796241
[TBL] [Abstract][Full Text] [Related]
18. Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus.
Tsuge M; Uchida T; Hiraga N; Kan H; Makokha GN; Abe-Chayama H; Miki D; Imamura M; Ochi H; Hayes CN; Shimozono R; Iwamura T; Narumi H; Suzuki T; Kainoh M; Taniguchi T; Chayama K
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373196
[TBL] [Abstract][Full Text] [Related]
19. [Nucleos(t)ides as prophylaxis for the reactivation of hepatitis B virus in immunosuppressed patients].
Fan LY; Zhou Z; Zhong S; Ling N; Wang ZY; Shi XF; Zhang DZ; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2009 Jun; 17(6):429-33. PubMed ID: 19567021
[TBL] [Abstract][Full Text] [Related]
20. Aiming for cure in HBV and HDV infection.
Petersen J; Thompson AJ; Levrero M
J Hepatol; 2016 Oct; 65(4):835-848. PubMed ID: 27270043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
